Summary
Pfizer Inc. (PFE) filed an 8-K on January 3, 2005, reporting a significant event from December 31, 2004. The company announced that it has received U.S. Food and Drug Administration (FDA) approval to market its new drug, Lyrica™ (pregabalin capsules). This FDA approval allows Pfizer to market Lyrica for the management of neuropathic pain associated with two specific conditions: diabetic peripheral neuropathy and postherpetic neuralgia. This development is crucial for investors as it represents the launch of a potentially significant new product in Pfizer's pipeline, addressing unmet medical needs in pain management. The press release detailing this approval is included as an exhibit to the filing, providing further context on the drug's indications and potential market.
Key Highlights
- 1Pfizer Inc. received FDA approval for Lyrica™ (pregabalin capsules) on December 31, 2004.
- 2Lyrica is approved for managing neuropathic pain.
- 3Specific approved indications include pain associated with diabetic peripheral neuropathy.
- 4Lyrica is also approved for pain associated with postherpetic neuralgia.
- 5The announcement was made via a press release filed as an exhibit to the 8-K.
- 6This marks the introduction of a new therapeutic product to Pfizer's market offerings.